Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment

Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment

Abstract Background and Objective Durvalumab plus tremelimumab (Durva/Treme) has recently been approved as a first-line or later-line treatment for patients with unresectable hepatocellular carcinoma (u-HCC) in Japan. We assessed the real-world outcomes of Durva/Treme for u-HCC, with a focus on trea...

Full description

Bibliographic Details
Main Authors: Yudai Fujiwara, Hidekatsu Kuroda, Tamami Abe, Keisuke Kakisaka, Ippeki Nakaya, Asami Ito, Takuya Watanabe, Kenji Yusa, Tomoaki Nagasawa, Hiroki Sato, Akiko Suzuki, Kei Endo, Yuichi Yoshida, Takayoshi Oikawa, Kei Sawara, Akio Miyasaka, Takayuki Matsumoto
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-10-01
Series:Drugs - Real World Outcomes
Online Access:https://doi.org/10.1007/s40801-024-00458-7

Internet

https://doi.org/10.1007/s40801-024-00458-7

Similar Items